Dr. Thomas Werner Elected to Accera, Inc.’s Board of Directors

BROOMFIELD, Colorado - Accera, Inc., a biotechnology company delivering breakthrough therapies
in central nervous system (CNS) diseases, announced today that Thomas Werner,
Ph.D. has been elected to its board of directors.

Since 2001, Dr. Werner has been a managing director and senior vice
president of GlaxoSmithKline (GSK) and has served as CEO of the GSK
Foundation until earlier this year. He led the Pharmaceutical Research
Manufacturers of America (PhRMA) in Germany as its chairman through November
2008. He began his pharmaceutical career with Squibb Pharma Germany where he
held sales, marketing and brand management positions from 1983-1989 and later
held executive management positions at Bristol-Myers Squibb. Dr. Werner
earned his Ph.D. in chemistry at the University of Gottingen in Germany.

Dr. Werner was instrumental in the successful growth strategies and
leadership of the German subsidiaries of GSK and Bristol-Myers Squibb. He
grew sales of the ACE inhibitor, Captopril, to become the largest
pharmaceutical product in Germany, and developed Viani, an asthma drug, into
one of the leading pharmaceutical products in Germany.

Dr. Werner co-founded the Genetic Research Center, a joint venture with
the Max Planck Institute for Psychiatry and the Ludwig-Maximilians-University,
both in Munich. He is a member of the Board of Trustees of the Paul Ehrlich
Association and the Robert Koch Foundation.

“We are delighted to welcome Dr. Werner to our board of directors,” said
Steve Orndorff, Ph.D., Accera’s founder and CEO. “Thomas has a demonstrated
record of success in the management and leadership of European subsidiaries
of internationally acclaimed pharmaceutical companies. With Accera’s recent
US product launch of Axona(TM) for Alzheimer’s disease, Dr. Werner’s
experience in the commercialization of several highly successful drug
products will be invaluable.”

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and
develops therapeutic breakthroughs in central nervous systems disorders.
Accera’s novel approaches positively impact patients with neurodegenerative
disorders who are in need of effective, well-tolerated therapies. Through its
proprietary scientific platform, Accera is developing products that address
metabolic deficiencies associated with certain neurodegenerative diseases by
providing an alternative energy source for the brain. For more information,
visit www.accerapharma.com.

Contacts: Richard Lewis Communications, Inc.
Accera, Inc. +1-212-827-0020
+1-303-999-3710 Gregory Tiberend, Media
Steve Orndorff, Ph.D. gtiberend@rlcinc.com
Founder, President and CEO Cecelia Heer, Investors
sorndorff@accerapharm.com cheer@rlcinc.com

Source: Accera, Inc.

Steve Orndorff, Ph.D., Founder, President and CEO of Accera, Inc., +1-303-999-3710, sorndorff at accerapharm.com; or Media, Gregory Tiberend, gtiberend at rlcinc.com, or Investors, Cecelia Heer, cheer at rlcinc.com, both of Richard Lewis Communications, Inc., +1-212-827-0020, for Accera, Inc.